Franklin Resources Inc Puma Biotechnology, Inc. Transaction History

Franklin Resources Inc

$334 Billion
Q3 2024

A detailed history of Franklin Resources Inc transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Franklin Resources Inc holds 15,967 shares of PBYI stock, worth $46,304. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,967

Previous 15,967 -0.0%

Holding current value

$46,304

Previous $40,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.25 - $4.03 $35,925 - $64,347	15,967 New	15,967 $40,000
Q3 2023 Nov 13, 2023	SELL	$2.63 - $4.09 $13,339 - $20,744	-5,072 Reduced 20.93%	19,162 $50,000
Q3 2022 Nov 14, 2022	BUY	$2.27 - $3.84 $569 - $963	251 Added 1.05%	24,234 $57,000
Q2 2022 Aug 11, 2022	SELL	$1.64 - $3.3 $19,051 - $38,336	-11,617 Reduced 32.63%	23,983 $68,000
Q1 2022 May 13, 2022	BUY	$2.13 - $3.24 $75,828 - $115,344	35,600 New	35,600 $103,000
Q4 2018 Feb 12, 2019	SELL	$20.07 - $46.7 $12.6 Million - $29.3 Million	-628,230 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$41.2 - $59.85 $5.01 Million - $7.28 Million	-121,615 Reduced 16.22%	628,230 $28.8 Million
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $5.13 Million - $7.25 Million	-106,155 Reduced 12.4%	749,845 $44.4 Million
Q1 2018 May 10, 2018	BUY	$59.7 - $99.25 $1.29 Million - $2.14 Million	21,600 Added 2.59%	856,000 $58.3 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $272,165 - $384,104	2,900 Added 0.35%	834,400 $82.5 Million
Q3 2017 Nov 13, 2017	BUY	$72.0 - $119.75 $59.9 Million - $99.6 Million	831,500	831,500 $99.6 Million

Others Institutions Holding PBYI

# of Institutions

102

Shares Held

29.1M

Call Options Held

60.6K

Put Options Held

16.3K

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Resources Inc, based on Form 13F filings with the SEC.

News

Stay updated on Franklin Resources Inc with notifications on news.

Account

Franklin Resources Inc Puma Biotechnology, Inc. Transaction History